期刊
PERFUSION-UK
卷 22, 期 3, 页码 207-210出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/0267659107081632
关键词
insulin; hyperglycemia; cardiopulmonary bypass; biomaterials
资金
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079206] Funding Source: NIH RePORTER
- NHLBI NIH HHS [R01 HL079206-01] Funding Source: Medline
Hyperglycemia associated with cardiopulmonary bypass (CPB) is an independent predictor of morbidity and mortality. One suggested cause of hyperglycemia during CPB is a decline of serum insulin concentrations. Since plasma C-proteins are not reduced during CPB suggesting that pancreatic insulin secretion is not affected - the reduction of insulin concentrations is hypothesized to be due to the binding of the insulin protein to the CPB biomaterials. The hypothesis of this study is that insulin binds to the CPB polyvinyl chloride (PVC) tubing and that selected bio-coatings inhibit this process. Human insulin was diluted to a physiologic concentration of 30 mu U/mL in saline and exposed to four types of sterile PVC tubing, namely: uncoated, Terumo X-coated, Medtronic Carmeda, and Cobe SMARxT for 30 minutes at 37 degrees C. Insulin concentrations were determined with ELISA. The recovered insulin concentrations were found to be 9.3 +/- 0.6 mu U/mL in the uncoated (control), 17.7 +/- 1.9 mu U/ml, in the X-coating, 17.9 +/- 1.1 mu U/mL, in the Carmeda, and 14.28 +/- 0.17 mu U/mL in the SMAR(x)T coated tubing. These data support the hypothesis that the insulin binding to the PVC tubing can be reduced by 48% and up to 35% with X-coating and Carmeda, and SMAR(x)T coating, respectively. Therefore, the use of coated CPB systems is justified to reduce CPB-associated hyperglycemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据